Eagle Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Eagle Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-318,354	Closed	-$37.7M	–	619
2022 Q1	$37.7M	Sell	318,354 -15,162	-5%	-$1.89M	0.19%	152
2021 Q4	$46.1M	Sell	333,516 -1,946	-0.6%	-$247K	0.2%	153
2021 Q3	$46.6M	Sell	335,462 -54,260	-14%	-$6.77M	0.21%	159
2021 Q2	$37.8M	Sell	389,722 -14,160	-4%	-$1.15M	0.16%	179
2021 Q1	$27.6M	Sell	403,882 -154,904	-28%	-$12.5M	0.12%	210
2020 Q4	$47.9M	Sell	558,786 -92,379	-14%	-$7.83M	0.27%	136
2020 Q3	$41.1M	Buy	651,165 +6,386	+1%	+$419K	0.21%	164
2020 Q2	$44.7M	Sell	644,779 -96,940	-13%	-$5.16M	0.25%	144
2020 Q1	$25.2M	Sell	741,719 -4,830	-0.6%	-$221K	0.16%	189
2019 Q4	$40.6M	Sell	746,549 -237,786	-24%	-$11.8M	0.2%	188
2019 Q3	$41.1M	Buy	+984,335	New	+$41.6M	0.21%	170

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eagle Asset Management's BHVN Position: Q2 2022 in Review

Eagle Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 318,354 shares — an estimated $37.7M sold.

Eagle Asset Management first reported a position in BHVN in Q3 2019 and held it in 11 quarters. The position peaked at $47.9M in Q4 2020. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Eagle Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Eagle Asset Management sold 318,354 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $37.7M.
Eagle Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019 and held it in 11 quarters.
Eagle Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $47.9M in Q4 2020.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Eagle Asset Management's 13F filing for Q2 2022, filed 10 Aug 2022.